Published in J Virol on July 02, 2008
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Patterns of resistance development with integrase inhibitors in HIV. Infect Drug Resist (2011) 1.17
Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother (2010) 1.16
Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS (2011) 1.11
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis (2012) 1.09
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology (2009) 1.05
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother (2010) 1.04
A dynamic model of HIV integrase inhibition and drug resistance. J Mol Biol (2010) 0.99
HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. Retrovirology (2009) 0.97
HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses (2010) 0.90
Subtype-associated differences in HIV-1 reverse transcription affect the viral replication. Retrovirology (2010) 0.89
HIV resistance to raltegravir. Eur J Med Res (2009) 0.89
Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob Agents Chemother (2013) 0.82
Raltegravir: The evidence of its therapeutic value in HIV-1 infection. Core Evid (2010) 0.81
Consensus HIV-1 FSU-A integrase gene variants electroporated into mice induce polyfunctional antigen-specific CD4+ and CD8+ T cells. PLoS One (2013) 0.80
Amino acid covariation in a functionally important human immunodeficiency virus type 1 protein region is associated with population subdivision. Genetics (2009) 0.79
Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance. Antivir Ther (2009) 0.77
Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. PLoS One (2017) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
The accuracy of reverse transcriptase from HIV-1. Science (1988) 8.24
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol (1992) 6.77
HIV-1 nomenclature proposal. Science (2000) 6.61
Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Virol (1992) 6.07
Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J (1993) 4.39
The causes and consequences of HIV evolution. Nat Rev Genet (2004) 4.34
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol (1992) 3.85
Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J (2001) 3.23
Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis. Proc Natl Acad Sci U S A (1993) 3.20
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A (2004) 2.55
Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res (1994) 1.98
HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol (2007) 1.78
EMBOSS opens up sequence analysis. European Molecular Biology Open Software Suite. Brief Bioinform (2002) 1.77
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology (2007) 1.55
A statistical model for HIV-1 sequence classification using the subtype analyser (STAR). Bioinformatics (2005) 1.55
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol (2003) 1.54
The fastest genome evolution ever described: HIV variation in situ. Curr Opin Genet Dev (1993) 1.47
S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs (2003) 1.31
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS (2004) 1.28
Covariability of selected amino acid positions for HIV type 1 subtypes C and B. AIDS Res Hum Retroviruses (2005) 1.15
Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors. Antimicrob Agents Chemother (2006) 1.02
A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett (2005) 0.91
The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS (2006) 0.90
Associations between amino acids in the evolution of HIV type 1 protease sequences under indinavir therapy. AIDS Res Hum Retroviruses (1999) 0.90
Antiretroviral resistance in clinical practice. Int J STD AIDS (2001) 0.80
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis (2009) 3.37
Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis (2013) 3.35
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis (2008) 3.15
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups. Proc Natl Acad Sci U S A (2005) 3.04
Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog (2009) 2.92
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology (2010) 2.90
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS (2004) 2.35
Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci U S A (2009) 2.21
Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med (2005) 2.04
Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis (2009) 1.96
Update of the Drug Resistance Mutations in HIV-1: 2005. Top HIV Med (2005) 1.83
Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS (2010) 1.82
The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics (2009) 1.80
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (2012) 1.71
Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals. J Virol (2009) 1.70
Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med (2004) 1.62
Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr (2004) 1.61
Optimal use of maraviroc in clinical practice. AIDS (2008) 1.60
Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. J Virol (2007) 1.57
The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS (2002) 1.50
Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol (2012) 1.45
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther (2008) 1.41
Limitations of proposed novel trial design. AIDS (2012) 1.39
Drug resistance mutations in HIV-1. Top HIV Med (2004) 1.37
Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol (2009) 1.37
World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther (2008) 1.36
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis (2010) 1.36
The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr (2008) 1.35
Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J Infect Dis (2004) 1.35
Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet (2004) 1.33
Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS (2010) 1.29
Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis (2013) 1.26
Transmission of HIV-1 drug resistance. J Clin Virol (2004) 1.24
The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One (2010) 1.19
Phylogenetic insights into regional HIV transmission. AIDS (2012) 1.18
Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS (2006) 1.14
Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr (2005) 1.14
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J (2008) 1.13
Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. J Infect Dis (2009) 1.12
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med (2010) 1.12
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy. Clin Infect Dis (2013) 1.12
HIV resistance and the developing world. Int J Antimicrob Agents (2007) 1.10
Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J Antimicrob Chemother (2008) 1.10
Investigation of HIV-1 transmission events by phylogenetic methods: requirement for scientific rigour. AIDS (2005) 1.10
Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clin Infect Dis (2012) 1.09
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrob Agents Chemother (2010) 1.09
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother (2006) 1.08
HIV phylogenetics. BMJ (2007) 1.07
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS (2008) 1.07
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica (2009) 1.07
Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions. AIDS (2014) 1.06
Constructing the cascade of HIV care: methods for measurement. Curr Opin HIV AIDS (2016) 1.04
No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort. PLoS One (2011) 1.04
Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest? J Acquir Immune Defic Syndr (2014) 1.03
Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. J Gen Virol (2013) 1.02
Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res (2010) 1.02
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring. J Acquir Immune Defic Syndr (2010) 1.01
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS (2010) 1.01
Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther (2006) 0.99
When and how to use maraviroc in HIV-infected patients. AIDS (2009) 0.99
Testing for HIV: concise guidance. Clin Med (2009) 0.98
Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring. PLoS One (2012) 0.98
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One (2013) 0.97
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther (2010) 0.96
Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. Antimicrob Agents Chemother (2011) 0.96
Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology (2013) 0.96
The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients. AIDS (2002) 0.95
The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS (2009) 0.94
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). Antivir Ther (2012) 0.94
Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS (2004) 0.93
Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS (2002) 0.93
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med (2009) 0.93
The immunological and virological consequences of planned treatment interruptions in children with HIV infection. PLoS One (2013) 0.92